NSTMNovelStem International Corp.

About NovelStem International Corp. (NSTM)

NovelStem International Corp. (NSTM) is a Diagnostics & Research company headquartered in Boca Raton, FL, United States whose shares trade over-the-counter on the Pink tier.

NovelStem owns a 33% stake in NewStem Ltd. which is advancing its novel stem-cell-based diagnostic technology for predicting patients resistance to cancer therapies, allowing for better, targeted cancer treatments with the potential to reduce incidents of drug resistance. The technology is also being used for genetic research related to other medical therapies. NovelStem recently increased its ownership to 33% from 27.3% based upon completion of an additional $1M investment on top of $3M that was invested prior, for a total investment of $4M in NewStem. NovelStem also has a 50% stake in Netco Partners, which owns the Net Force publishing franchise. NewStem is advancing novel stem-cell-based technology utilized for the development of new diagnostics and therapeutics. The most advanced product of NewStem is a diagnostic predicting patients resistance to cancer therapy, allowing for better, targeted personal-oncology treatments with the potential to reduce incidents of anti-cancer drug resistance. NewStem is a spinoff of Yissum, The Hebrew University of Jerusalems technology-transfer company. NewStems diagnostic solutions are based on the research of human haploid pluripotent stem cells (hHPSCs) by Professor Nissim Benvenisty, Director of the Azrieli Center for Stem Cells & Genetic Research at Hebrew University. NewStem holds the intellectual property, reagents & experience required for hHPSC isolation, differentiation, genetic manipulation, immunogenicity & tumorigenicity.

Products and services

The company owns novel stem-cell-based diagnostic technology for predicting patients' resistance to cancer therapies, allowing for better, targeted cancer treatments with the potential to reduce incidents of drug resistance. The technology is also being used for genetic research related to other medical therapies.

NSTM key facts

Ticker symbol

NSTM

Market tier

Pink

Sector

Healthcare

Industry

Diagnostics & Research

Headquarters

Boca Raton, FL, United States

Country of incorporation

US

Year of incorporation

1993

Estimated market cap

$379.7K (as of May 13, 2025)

Shares outstanding

46,881,475

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

12/31

NovelStem International Corp. leadership

• Jan Loeb — CEO
• William Jones — Other

Explore more: Diagnostics & Research stocks · Healthcare sector · Pink stocks · OTC stocks starting with N